Shanghai-based pharmaceutical and medical device firm WuXi AppTec has led a strategic funding round in Insilico Medicine, a Baltimore-based artificial intelligence company specializing in the application of deep learning for target identification, drug discovery and aging research. Financial details of the deal were not disclosed. Pavilion Capital, a subsidiary of Temasek Holdings, venture capital firm Bold Capital Partners and therapeutics company Juvenescence also participated in the round, according to Insilico Medicine’s announcement. Insilico Medicine focuses on the application of generative … WuXi AppTec Leads Strategic Funding In US Healthcare AI Firm Insilico Medicine appeared first on China Money Network.